Join BJS Academy
BJS Academy>Randomized clinical ...>Omitting axillary di...
Normal View Dyslexic View

Omitting axillary dissection in breast cancer with sentinel-node metastases.

20 June 2024
Randomized clinical trials Breast
de Boniface J, Tvedskov TF, Rydén L, Szulkin R, Reimer T, Kühn T, for the SENOMAC Trialists’ Group.

N Engl J Med 2024; 390: 1163-1175.

Some 2766 patients with breast cancer and 1-2 positive nodes on sentinel lymph node biopsy were randomly allocated to axillary dissection or no surgery. Adjuvant treatment was similar in both groups. 5-year recurrence free survival was similar: 89.7 per cent in controls and 88.7 per cent in the axillary dissection group.

Comment: Very important trial that questions the need for a procedure that has a number of significant local complications and adverse effects on quality of life, without any evidence for survival benefit.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct011
Randomized clinical trials
Randomized clinical trials
Breast
Omitting axillary dissection in breast cancer with sentinel-node metastases.
de Boniface J, Tvedskov TF, Rydén L, Szulkin R, Reimer T, Kühn T, for the SENOMAC Trialists’ Group.
20062024
N Engl J Med 2024; 390: 1163-1175.
Some 2766 patients with breast cancer and 1-2 positive nodes on sentinel lymph node biopsy were randomly allocated to axillary dissection or no surgery. Adjuvant treatment was similar in both groups. 5-year recurrence free survival was similar: 89.7 per cent in controls and 88.7 per cent in the axillary dissection group.
Comment: Very important trial that questions the need for a procedure that has a number of significant local complications and adverse effects on quality of life, without any evidence for survival benefit.
Published on: 20 June 2024
Article ID: rct011

Related articles

Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.

Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.

16 August 2024

21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF et al.
N Engl J Med 2021; 385: 2336-2347

1 January 2022

Event-free survival with pembrolizumab in early triple-negative breast cancer.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S et al, for the KEYNOTE-522 Investigators.
N Engl J Med 2022; 386: 556-567.

1 March 2022
Home
  • Normal view
  • Dyslexic view
Info
Copied!